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We hypothesized that rho/rho kinase plays a role in sex diﬀerences in vascular dysfunction of diabetics. Contractions to serotonin
were greater in isolated aortic rings from nondiabetic males versus females and increased further in streptozotocin-induced
diabetic males but not females. The increased contractions to serotonin in males were reduced by inhibitors of rho kinase (fasudil,
Y27632 and H1152) despite no change in expression of rhoA or rho kinase. Contractions to U46619 were not altered by fasudil
or Y27632 or the presence of diabetes. In contrast to acute eﬀects of fasudil, chronic treatment with fasudil increased contractions
to serotonin in aorta from both non-diabetic and diabetic males. In summary, serotonin-induced contractions were increased
in aorta from diabetic males but not females. Although administration of rho kinase inhibitors acutely decreased contractions
to serotonin, long-term treatment with fasudil increased contractions. Long-term fasudil treatment may increase compensatory
mechanisms to enhance vasoconstrictions.
1.Introduction
Typically women develop cardiovascular disease 10–15 years
later than age-matched men; however, the beneﬁts of female
sexmaynotextendtodiabetes.Epidemiologicalstudiesrelat-
ing development of cardiovascular disease in diabetics with
sex have not generated consistent results. While some studies
have concluded that female sex and hormone replacement
therapy reduce the risk of cardiovascular disease even in
the presence of diabetes [1–3], others suggest that diabetes
abolishes the beneﬁts of female sex or even increases the
risk of developing cardiovascular disease in women [4–10].
Studies in animal models of diabetes, in general, suggest
a protective advantage or no eﬀect of female sex [11–14].
Even in the absence of any protective eﬀect of female sex,
the underlying mechanisms responsible for alterations in
vascular function may diﬀer in male versus female diabetics.
The authors [15] and others [16] have demonstrated
that sex diﬀerences in signaling pathways within vascular
muscle contribute to diﬀerences in contractile function.
Arteries from male mice contract to a greater magnitude
to selected agonists compared to arteries from females [15,
17, 18]. This diﬀerence in contractile response was not
related to the contribution of nitric oxide (NO) but rather
due to agonist-speciﬁc activation of signaling pathways that
regulate calcium sensitivity of contractile proteins. Activa-
tion of both rhoA and rho kinase which regulate myosin
light chain phosphorylation was greater in arteries from
males compared to females [15]. Rho/rho kinase signaling
is increased in hypertension and atherosclerosis and may
contribute to alterations in vascular function and heightened
contractile states such as cerebral and coronary vasospasm
[19]. In light of the sex diﬀerence in the activation of
this pathway within blood vessels, we hypothesized that a
sex-dependent diﬀerence in rho and rho kinase activation
may contribute to diﬀerences in vascular dysfunction in
male compared to female diabetics. We demonstrated in a
model of Type 2 diabetes that serotonin-induced contractile2 Experimental Diabetes Research
responses were increased in aorta from both males and
females but activation of rhoA and rho kinase was increased
only in diabetic males and not females [20]. Thus, despite
similar contractile dysfunction in arteries from male and
female Type 2 diabetics, the dysfunction in diabetic males
demonstrated greater dependence upon activation of rhoA
and rho kinase. We concluded that alternative mechanisms
regulating vasoconstriction may play a greater role in
females.
The goals of the present study were ﬁrst, to determine
whethersexdiﬀerencesincontractilefunctionwereobserved
in a model of Type 1 diabetes (streptozotocin-induced
insulinopenia) and whether this was due to a diﬀerence
in rho kinase signaling. We hypothesized that vascular
dysfunction may be greater in arteries from Type 1 diabetic
males compared to females due, in part, to a greater
activation of rho/rho kinase signaling. The second goal
was to determine whether chronic inhibition of rho kinase
would prevent the development of vascular dysfunction in
diabetic males. We hypothesized that if an increase in rho
kinase activity contributed to the contractile dysfunction in
diabetes then treatment with a rho kinase inhibitor may
protect the arteries. To test these hypotheses, we compared
reactivity of arteries from streptozotocin-induced diabetic
male and female mice to nondiabetics. To determine the role
of rhoA and rho kinase, we compared eﬀects of speciﬁc rho
kinase inhibitors on contractile responses in arteries from
nondiabetic compared to diabetic males and females. Finally,
we tested whether chronic administration of a rho kinase
inhibitor to streptozotocin-induced diabetic mice would
prevent development of vascular dysfunction.
2.MaterialsandMethods
2.1. Experimental Model. The animal protocol was reviewed
andapprovedbytheAnimalCareandUseCommitteesatthe
Department of Veterans Aﬀairs Iowa City Health Care Sys-
tem and the University of Iowa. All animal procedures com-
plied with the “Guiding Principals for Research Involving
Animals and Human Beings” of the American Physiological
Society. Diabetes was induced in male and female C57BL6
mice 5-6 weeks of age by injection with streptozotocin (2-3
injections,100–150mg/kgip)approximatelyoneweekapart.
Mice were weighed and blood glucose was measured weekly.
Diabetes was conﬁrmed when blood glucose levels exceeded
300mg/dl.
2.2. Measurement of Vascular Reactivity. Studies were per-
formed in aorta since it is the most commonly used mouse
vascular model studied to date and allows us to compare
vascular reactivity with protein expression and activity in the
same vessel type. Responses of aorta were measured using
previously published methods [15, 17, 20]. Nondiabetic
and diabetic mice (12–16 weeks post ﬁrst measurement
of hyperglycemia) were anesthetized with pentobarbital
(150mg/kg ip), and the thoracic aorta was rapidly removed
a n dp l a c e di ni c e - c o l dK r e b sb u ﬀer (mmol/L: NaCl 118.3,
KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3
25, and glucose 11). Aorta was cut into rings (3-4mm
in length) and mounted on wires connected to a force
transducer in an organ bath ﬁlled with Krebs at 37◦C
aerated with 20% O2,5 %C O 2, and balance N2. Tension was
increased to 0.75g over 60 minutes. To measure relaxation,
rings were initially contracted with U46619 (10–20nM) to
maintain a stable contraction of 50%–60% of maximum
beforeaddition ofacetylcholine(10nMto10μM)orsodium
nitroprusside (10nM to 10μM). Relaxation responses were
expressed as percent decrease in tension from the initial
contraction. Contractile responses to serotonin (10nM to
1μM)orthethromboxanemimeticU46619(10nMto1μM)
were obtained by adding increasing concentrations to vessels
under basal conditions. In general, 1-2 rings of aorta from
each animal were used as controls and 1-2 were treated with
inhibitors for 30 minutes prior to initiation of concentration
response curves. A minimal contraction of 250mg to KCl
(75–100mM) and greater than 50% relaxation to nitroprus-
side (10μM) was considered acceptable for inclusion in the
study. In some groups contractions were compared before
and after inhibition of rho kinase with fasudil (1-(5-Iso-
quinolinesulfonyl) homopiperazine hydrochloride, 10μM),
Y27632 (trans-4-[(1R)-1-Aminoethyl]-N-4-pyridinylcyclo-
hexanecarboxamide dihydrochloride, 1μM), or H1152 ((S)-
(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl) sulfonyl]-hexa-
hydro-1H-1,4-diazepinedihydrochloride,1μM).Fasudilwas
used because of its clinical use in the treatment of cerebral
vasospasm but it also inhibits protein kinase A (PKA), C
(PKC), and G (PKG), myosin light chain kinase (MLCK),
and CAM kinase II [21]. Y27632 which competes with ATP
for binding to the catalytic domain of rho kinase is 100
times more speciﬁc for rho kinase compared to PKA, PKC,
or MLCK [22, 23]. H1152 is a more speciﬁc and eﬃcacious
inhibitor of rho kinase than fasudil or Y27632 and a poor
inhibitor of the serine/threonine kinases, PKA, PKC, and
MLCK [24–26].
Fasudil is approved for use in the treatment of cere-
bral vasospasm after subarachnoid hemorrhage in Japan
and clinical trials suggest that it is beneﬁcial in the
treatment of angina [27]. To determine whether chronic
inhibition of rho kinase with fasudil protects arteries
of Type 1 diabetics from development of dysfunction,
streptozotocin-treated male mice and age-matched nondi-
abetic mice were administered fasudil (100mg/kg/day) in
their drinking water for 12–15 weeks prior to study [28, 29].
Responses of isolated rings of aorta were compared to age-
matched nontreated nondiabetics and diabetics as described
above.
2.3. Western Blot Analysis. Aortas (3-4 aorta pooled per
sample) from nondiabetic and diabetic mice were isolated
and ﬂash frozen in liquid nitrogen, minced, and sonicated
in buﬀer containing 25mM sucrose, 50mM MOPS, 2mM
EDTA; 2mM EGTA pH 7.4, Complete Protease Inhibitor
(Roche Molecular Biochemicals), 50mM NaF, 20mM
Na pyrophosphate, 1mM p-Nitrophenyl phosphate, and
1μM Microcystin LR. The homogenate was centrifuged at
14,000×gf o r1 5m i n u t e sa t4 ◦Ca n dp r o t e i nc o n c e n t r a t i o n sExperimental Diabetes Research 3
Table 1: Body weight and blood glucose levels in nondiabetic and
streptozotocin-treated diabetic mice.
n Weight (g) Glucose (mg/dl)
Nondiabetic Male 28 27.9 ±0.4 186 ±12
Diabetic Male 37 22.6 ±0.6† 510 ±9†
Nondiabetic Female 20 23.0 ±0.5∗ 184 ±12
Diabetic Female 28 19.2 ±0.5†∗ 434 ±16†∗
Mean ± SEM, †P<. 05 versus same sex Nondiabetic, and ∗P<. 05 versus
Male.
were determined in the supernatant by the bicinchoninic
acid method. Equal amounts of protein (30 or 50μg) were
separated by SDS-PAGE gel electrophoresis. After blocking
in milk, immunoblotting was performed using anti-rhoA
(1:250, Santa Cruz), anti-rho kinase (ROCK1 or ROCK2,
1:500, BD Biosciences), or α-actin (1:500, Sigma) in 3%
diluent followed by secondary antibodies conjugated with
horseradish peroxidase. Immunoreactivity was visualized
with enhanced chemiluminescence. Blots were digitized and
normalized to actin for comparison (NIH Image).
2.4. Materials. All chemicals were purchased from Sigma-
Aldrich unless otherwise noted. Y27632 and H1152 were
purchased from Tocris Bioscience and U46619 from Biomol.
Fasudil was purchased from Tocris and LC Laboratories.
2.5. Statistical Analysis. A l ld a t aa r ep r e s e n t e da sm e a n
±SEM. Responses of multiple rings from a given animal
treated similarly were averaged and “n”r e p r e s e n t sn u m b e r s
ofmicepergroup.Concentrationresponsecurveswerecom-
paredbyrepeatedmeasuresoratwo-wayanalysisofvariance
followed by Bonferroni. Data from immunoblots were com-
pared by Student t tests. Signiﬁcance was deﬁned at P<. 05.
3. Results
3.1. Development of Hyperglycemia in Males and Females.
Body weights and blood glucose levels for all groups are
listed in Table 1.B l o o dg l u c o s el e v e l sw e r es i m i l a rf o r
age-matched nondiabetic male and female mice. Following
injection with streptozotocin, levels of blood glucose were
more than doubled in both male and female mice (P<. 05
versus nondiabetic). The increase in blood glucose levels was
signiﬁcantly greater in males compared to females (P<. 05).
Both nondiabetic and diabetic females weighed less than
males and diabetic mice weighed less than nondiabetic mice
(Table 1).
3.2. Sex-Dependent Diﬀerences in Relaxation Responses in
Diabetes. Similar to our previous ﬁndings [15], NO-
mediated relaxation in response to acetylcholine and nitro-
prusside was similar in aorta from nondiabetic male and
female mice (Figure 1). In aorta from diabetic males, there
was a modest but signiﬁcant reduction in relaxation to
acetylcholine following development of hyperglycemia com-
pared to nondiabetics (Figure 1(a)), however, diﬀerences in
relaxation were not signiﬁcant at any individual concentra-
tion of acetylcholine. In contrast, there was no change in
relaxation in response to acetylcholine in aorta from diabetic
females (Figure 1(b)). Relaxation in response to nitroprus-
side was increased at lower concentrations in arteries from
both male and female diabetics compared to nondiabetics
(Figures 1(c) and 1(d)). These results suggest that after 12–
16 weeks of diabetes NO-mediated endothelium-dependent
dilation is modestly impaired in males but not females.
In contrast, relaxation of vascular muscle to exogenously
administered NO released from nitroprusside is increased
when relaxation to acetylcholine is either not altered or only
minimally diminished.
3.3. Sex-Dependent Diﬀerences in Contractile Responses in
Diabetes. In nondiabetic mice, contractions to serotonin
were greater in aorta from males compared to females
(Figures 2(a) and 2(b)) similar to our previous stud-
ies demonstrating sex-dependent diﬀerences in contractile
responses to serotonin [15, 17]. Contractions of aorta from
male mice were greater at 0.1 and 1μM serotonin (P<. 05)
compared to responses of aorta from females. In addition to
a greater response to serotonin of aorta from nondiabetic
males, contractions to serotonin were increased only in
diabetic males and not diabetic females (Figures 2(a) and
2(b)). Maximal contractions of aorta from diabetic males to
serotonin were almost two-fold greater than contractions of
aorta from diabetic females.
3.4. Role of Rho Kinase in Sex-Dependent Contractions in
Type 1 Diabetics. Rho kinase plays a role in the increased
contractile responses of arteries in other models of diabetes
[20, 30, 31]. To examine the role of rho kinase in increased
contractile responses to serotonin in streptozotocin-induced
diabetes, we compared responses to serotonin before and
after inhibition of rho kinase with fasudil in aorta from
nondiabetic and diabetic males and females. Inhibition of
rho kinase with fasudil (10μM) inhibited contractions of
aorta from both diabetic males and females to serotonin by
approximately 50% (Figures 2(c) and 2(d)). In the presence
of fasudil, contractions of aorta from diabetic males to
serotoninweresigniﬁcantlygreaterat1and10μMc ompar ed
to responses of arteries from diabetic females.
Both Y27632 (1μM) and H1152 (1μM) inhibited con-
tractions to serotonin in aorta from nondiabetic and diabetic
male mice (Figure 3). In arteries from diabetic male mice,
inhibition of rho kinase with Y27632 and H1152 reduced
contractions to the levels in nondiabetic male mice. These
results suggest that a major component of the enhanced
contraction to serotonin in arteries from diabetic male mice
was mediated by activation of rho kinase.
To determine whether the sex diﬀerence in contractile
dysfunction in diabetics was agonist speciﬁc, we compared
responses to thromboxane A2 mimetic U46619 in aorta
from nondiabetic and diabetic mice. In nondiabetic mice,
aorta from males contracted more than females but only
at the lowest concentration of U46619 (10nM, P<. 05,4 Experimental Diabetes Research
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Figure 1: Relaxation of aorta from nondiabetic and diabetic males (left panels) and females (right panels) to acetylcholine ((a) and (b))
and nitroprusside ((c) and (d)). Relaxation to acetylcholine and nitroprusside was similar in nondiabetic males and females. Relaxation to
acetylcholine was impaired in male but not female diabetics. In contrast, relaxation to nitroprusside was increased in both male and female
diabetics (n = 8–14 per group, ∗P<. 05 versus nondiabetic).
data not shown). Maximal contractions were similar (0.1μM
males 1.19 ± 0.09g versus females 1.05 ± 0.06g). In
contrast to serotonin, contractions to U46619 were not
increased in aorta from either diabetic males or females
compared to nondiabetics (0.1μM: males1.31 ± 0.08g and
females 0.95 ± 0.07g). Contractions to U46619 were not
altered by fasudil or Y27632 but were decreased in aorta
from both nondiabetics and diabetics by H1152 (data not
shown). Thus, an increased contractile response was not a
generalized phenomenon of diabetic vasculature but speciﬁc
for serotonin in this model.
3.5. Expression of Rho Kinase and RhoA in Arteries from
Diabetic Mice. To determine whether the increase in con-
tractions to serotonin of aorta from diabetic males and not
females was due to a change in the expression of rho kinase,
we compared expression of ROCK1 and ROCK2 in aorta
fromnondiabeticanddiabeticmaleandfemalemice.Similar
to our previous ﬁndings [15], expression of ROCK1 and
ROCK2 was not diﬀerent between nondiabetic males and
females (Figures 4(a) and 4(b)). In addition, there was no
change in expression or either rho kinase isoform in aorta of
diabetics compared to nondiabetics (Figures 4(a) and 4(b)).
Since activation of rho kinase is regulated, in part, by
activation of the upstream rho GTPase, rhoA, we compared
expression of rhoA in aorta from nondiabetic and diabetic
males and females. Similar to our ﬁndings with rho kinase,
there was no diﬀerence in expression of rhoA in nondiabetic
males and females or between nondiabetics and diabetics
(Figure 4(c)). Thus, the increased activation of the rho/rho
kinase pathway in aorta from streptozotocin-induced dia-
betic mice was not due to a change in expression of either
rhoA or rho kinase.
3.6. Eﬀect of Chronic Treatment with Fasudil on Vascular
Dysfunction in Diabetic Mice. Since acute inhibition of rhoExperimental Diabetes Research 5
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Figure 2: Contractions of aorta from nondiabetic and diabetic males and females to serotonin. Contractions to serotonin were greater in
aorta from nondiabetic males (a) than females ((b) n = 13–15 per group, P<. 05). Following development of diabetes, contractions to
serotonin were increased in males ((a) n = 14) but not females ((b) n = 12, ∗P<. 05 nondiabetic versus diabetic). In diabetic males and
females inhibition of rho kinase with fasudil (10μM) reduced contractions to serotonin ((c) males, n = 5, (d) females, n = 8, †P<. 05
diabetic versus diabetic plus fasudil).
kinaserestoredcontractileresponsesofarteriesfromdiabetic
males to nondiabetic levels, we hypothesized that chronic
inhibition of rho kinase would prevent development of vas-
cular dysfunction in diabetics. Male mice were treated with
fasudil for 12–16 weeks upon development of hyperglycemia
(blood glucose over 300mg/dl). Treatment with fasudil
had no eﬀect on body weight or level of hyperglycemia
(Table 2). Measurements of vascular function at the end
of the treatment period revealed surprising results. Similar
to the previous results, contractions to serotonin were
increased in aorta from diabetic males while contractions
to U46619 were not diﬀerent from nondiabetics (Figure 5).
Interestingly, contractions to serotonin were increased in
aorta from both nondiabetic and diabetic mice treated with
fasudilcomparedtonontreatedmice(Figures5(a)and5(b)).
In fact, contractions to serotonin of aorta from nondiabetic
mice treated with fasudil were similar to contractions of
aorta from diabetic mice treated with fasudil. Contraction
in response to U46619 was not changed in diabetics and
was unaﬀected by treatment with fasudil in nondiabetics and
diabetics (Figure 5(c)). Thus, in contrast to acute inhibition
of rho kinase with fasudil, chronic treatment with fasudil
increased contractions to serotonin of arteries from both
nondiabetic and diabetic mice.
4. Discussion
There were several novel ﬁndings in the present study. First,
development of vascular dysfunction in a model of Type 16 Experimental Diabetes Research
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Figure 3: Eﬀects of rho kinase inhibitors Y27632 (1μM (a) and (b)) and H1152 (1μM (c) and (d)) on contractions to serotonin in aorta
from nondiabetic (left panels) and diabetic male mice (right panels). Inhibition of rho kinase with either Y27632 or H1152 decreased
contractions of aorta from both nondiabetic and diabetic mice to serotonin (nondiabetics n = 4–6 per group, diabetics n = 8p e rg r o u p ,
∗P<. 05 compared to paired untreated).
Table 2: Body weight and blood glucose levels in nondiabetic and
streptozotocin-treated diabetic male mice without and with fasudil
treatment (100mg/kg/day po).
n Weight (g) Glucose (mg/dl)
Nondiabetic 8 28.96 ±1 213 ±10
Nondiabetic plus Fasudil 8 30.17 ±1 200 ±8
Diabetic 10 26.07 ±1 458 ±32∗
Diabetic plus Fasudil 10 26.04 ±1 511 ±11∗
Mean ± SEM, ∗P<. 05 versus Nondiabetic.
diabeteswasdependentuponsex.Relaxationtoacetylcholine
wasmodestlyimpairedonlyinaortafrommalediabeticsand
not females. Contraction to serotonin was augmented only
in aorta from diabetic males and not females. This contrasts
with the augmented relaxation to nitroprusside which was
observed in arteries from both diabetic males and females.
Second, the sex-dependent diﬀerence in contractions to
serotonin may be related to an augmented activation of
rho kinase; however, neither expression of rhoA nor rho
kinase was increased in aorta of diabetic males compared to
nondiabetics. Third, activation of rho kinase played a greater
role in contractions to serotonin compared to U46619. This
diﬀerence in the rho kinase component of the response
may contribute to the greater contractions to serotonin
and not U46619 in diabetic arteries. Fourth, despite a
reduction in contractile response to serotonin in aorta from
both nondiabetic and diabetic males following acute fasudil
administration, chronic treatment with fasudil increased
contractions to serotonin in aorta from both nondiabetic
and diabetic mice. Fasudil treatment had no eﬀect on
contractions to U46619. These ﬁndings demonstrate that
chronic treatment with fasudil did not prevent developmentExperimental Diabetes Research 7
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Figure 4: Representative immunoblots and mean levels of protein expression of ROCK1 (a), ROCK2 (b), and rhoA (c) in aorta from
nondiabetic (ND) and diabetic (DB) males and females. Expression of rho kinase (ROCK1and ROCK2) and rhoA was not diﬀerent between
males and females or nondiabetics and diabetics (mean ± SEM normalized to actin, n = 5-6 pooled samples each containing nondiabetic
and diabetic males and females).
of vascular dysfunction in Type 1 diabetics but actually
enhanced contractions to serotonin.
The results of the present study, which demonstrate
sex-dependent diﬀerences in contractions to serotonin of
arteries from nondiabetic mice, are in agreement with our
previous studies [15, 17]. In the present study, contractions
to serotonin and not NO-mediated vasodilators were greater
in arteries from males compared to females. Although
numerous studies suggest that gonadal hormones regulate
expression of nitric oxide synthase and release of NO,
the authors and others have not detected diﬀerences in
vascular responses to NO-dependent vasodilators in arteries
from male compared to female mice [15, 32]. The reduced
vasoconstriction to serotonin in arteries from female mice
mediated by rho kinase [15] is in agreement with studies
demonstrating estrogen-induced decreases in rho/rho kinase
activity under basal conditions [16]. Although estrogen
at supraphysiological levels decreases transcript for rho
kinase in cultured cells [33], The authors and others have
demonstrated a sex diﬀerence in rho kinase activity despite
no diﬀerence in protein expression in arteries from male and
female mice [15, 16]. Results of the present study conﬁrmed
our previous results that expression of rhoA and rho kinase
wasnotdiﬀerentinaortabetweennondiabeticC57BL/6male
and female mice [15]. This diﬀerence in contractions to
serotonin of arteries from male compared to female mice has
not been demonstrated in all mouse strains suggesting that
genetic background inﬂuences the phenotype [20].
In addition to diﬀerences in responses to serotonin
depending on mouse strains, the model of diabetes also
inﬂuencescontractionsofarteriestoserotonin.Theresultsof
the previous and present studies suggest that the interaction
between sex and diabetes is dependent on the type of
diabetes. In our previous study in a leptin receptor deﬁcient
model of Type 2 diabetes, contractions of arteries from
diabetic female mice were increased to serotonin similar to
increases in arteries from diabetic male mice [20]. In Type
2 diabetic mice, female sex did not provide protection from
development of vascular dysfunction. However, there was a
sex-dependent diﬀerence in the mechanisms involved in the
dysfunction. There was no increase in protein expression of
either rhoA or rho kinase in arteries from either male or
female diabetic mice but activation of both rhoA and rho
kinase assessed biochemically was increased only in arteries
fromdiabeticmales[20].Inthepresentstudyourconclusion
that activation of rho kinase was increased in a model of
Type 1 diabetes is based on the ability of diﬀerent inhibitors
of rho kinase to signiﬁcantly reduce contractions of aorta8 Experimental Diabetes Research
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Figure 5: Eﬀects of chronic treatment with fasudil (100mg/kg/day, po) on contractions of aorta from nondiabetic and diabetic male mice to
serotonin ((a) and (b), resp.). In contrast to eﬀects of acute inhibition of rho kinase, chronic treatment with fasudil increased contractions
of aorta from both nondiabetics and diabetics to serotonin (∗P<. 05 versus untreated). Chronic treatment with fasudil had no eﬀect on
contractions to U46619 in aorta from either nondiabetics or diabetics (c).
to serotonin to levels measured in untreated nondiabetics.
In contrast to our previous study in Type 2 diabetics, there
was no diﬀerence in basal activation of either rhoA or rho
kinaseinaortafromnondiabeticversusType1diabeticmales
or females (data not shown). It is possible that diﬀerences
in activation of rhoA and rho kinase in Type 1 diabetics
may only be uncovered following serotonin administration.
Our data suggest that in both Type 1 and Type 2 models
of diabetes activation of the rhoA/rho kinase pathway may
be increased in arteries from diabetic males despite no
changeinproteinexpression.Theseresultssuggestthatother
mechanisms regulating activation of rhoA and rho kinase
m a yv a r yb ys e xa n da r ea l t e r e di nd i a b e t e s .
Diﬀerences in glucose and lipid metabolism in Type 1
versus Type 2 diabetes may also contribute to the mecha-
nisms underlying vascular dysfunction. Both forms of dia-
betesexhibitalteredglucoseregulation,buthyperlipidemiais
most frequently associated only with Type 2 diabetes. Hyper-
cholesterolemia alone increases activation of rho kinase and
calcium sensitization of vascular smooth muscle and may
contributetoalteredvascularfunctionindependentofeﬀects
of hyperglycemia [34]. Although blood glucose levels were
more than doubled in both streptozotocin-treated males and
females, the level of hyperglycemia was greater in males.
The association between hyperglycemia and vascular disease
with worse outcomes has been noted but the relationship
between vascular disease and glucose levels above 200mg/dl
has not been tested [35]. It is surprising in the present
study that despite glucose levels in females over 400mg/dl
little or no vascular dysfunction was found. Perhaps longer
durations of hyperglycemia are needed before protective
mechanisms are exhausted in blood vessels from femaleExperimental Diabetes Research 9
diabetics. These results also highlight the importance of
carefully considering the diabetic model under investigation.
Results from each model cannot necessarily be extrapolated
to the other.
Our ﬁndings that activity of rhoA and rho kinase
is increased in diabetic vasculature in the absence of a
change in protein expression highlight the complexity of the
mechanisms that regulate rho/rho kinase. Activation of rhoA
anddownstreamrhokinasecanberegulatedonseverallevels
independent of protein expression. First, inactive rhoA is
stored in the cytoplasm bound to GDP. Upon activation,
rhoA translocates to the plasma membrane and GTP must
be exchanged for GDP. These separate but integrated events
are under the control of a family of GTPase regulatory
proteins. Rho GTPase regulatory proteins (guanine disso-
ciation inhibitors, guanine exchange factors, and GTPase
activating proteins) control the balance between active and
inactiverhoA,bindingofGDPandGTP,andtranslocationof
rhoA to the plasma membrane. Variants in the gene for rho
guanine exchange factor which is involved in the exchange
of GTP for GDP are associated with impaired glucose
tolerance and Type 2 diabetes [36, 37]. Expression and/or
activity of these proteins may be regulated diﬀerently in
arteries from males compared to femalesand in nondiabetics
compared to diabetics. In addition to rhoA and rho kinase
contributing to alterations in contractile dysfunction in
diabetes, numerous studies have identiﬁed other signaling
pathways including protein kinase C contributing to changes
in calcium sensitization of contractile proteins in vascular
smooth muscle.
Another surprising ﬁnding in the present study was
the eﬀect of chronic treatment with fasudil on vascular
function. Studies with chronic treatment with fasudil in
animal models of hypertension and myocardial infarction
suggestthatinhibitionofrhokinasedecreasesbloodpressure
and improves cardiac function [19, 28, 29]. In an insulin-
resistant Type 2 model of diabetes in rats, fasudil prevented
the development but could not reverse established metabolic
abnormalities and nephropathy [38]. Several mechanisms
were proposed to account for the beneﬁts of fasudil treat-
ment. First, insulin signaling in skeletal muscle may be
augmented by fasudil to improve glucose metabolism since
excess activation of rho disrupted insulin signaling [39,
40]. Second, in mice genetically altered to produce excess
rho activation, adipogenesis was inhibited resulting in a
reduction in their overall size [39, 40]. It is unlikely that
an excess rho activation contributed to the weight loss in
our model of diabetes since fasudil treatment had no eﬀect
on body weight of diabetic mice. Third, inhibition of rho
kinase may inhibit macrophage inﬁltration, a contributing
factor to development of interstitial ﬁbrosis and vascular
disease [38]. The failure of fasudil to reverse diabetic
nephropathy once it was established was not fully explained
[38]. The beneﬁts of fasudil in prevention of diabetic
renal dysfunction contrast with the ﬁndings in the current
study where chronic treatment with fasudil did not prevent
development of vascular dysfunction but was associated with
augmented contractile responses to serotonin. This eﬀect
was speciﬁc for serotonin since contractions to thromboxane
mimetic U46619 were not aﬀected by chronic treatment
with fasudil. These disparate results with fasudil treatment
between our study in Type 1 diabetes and the previous
work in Type 2 diabetes may relate to diﬀerences in
target tissue (kidney versus vasculature) or insulin levels.
In our model of streptozotocin-induced diabetes, beta cells
and insulin levels are decreased; thus, inhibition of rho
kinase cannot improve insulin signaling. The diametrically
opposed eﬀects of acute versus chronic administration of
fasudil in our study highlight the need for continued
study of the role of rho kinase in vascular dysfunction in
diabetes.
Although the actions of fasudil, Y27632 and H1152, are
ascribed to their ability to inhibit rho kinase, the possibility
remains that other unidentiﬁed mechanisms are involved.
Comparisons of the speciﬁcity of these rho kinase inhibitors
against several protein kinases suggest that they are all
inhibitors of protein kinase A, C, G and even CAM kinase
II [21]. Although none are pure rho kinase inhibitors,
fasudil is the least and H1152 is the most speciﬁc [21].
Clinical trials in the treatment of cerebral vasospasm and
angina, however, have not identiﬁed serious adverse eﬀects
of fasudil beyond an increase in pyrexia [41, 42]. The
long-term consequences of inhibitors of rho kinase and
their speciﬁcity in the treatment of vascular disease in
patients with Type 1 versus Type 2 diabetes needs further
investigation prior to initiation of their wide spread use in
diabetics.
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